FDA is working on two ongoing research initiatives that will help it develop performance standards for generic formulations of abuse-deterrent opioids, in particular decision trees that will inform a step-wise approach that compares a generic to its reference-listed drug, Office of Generic Drugs Director, Division of Chemistry I, Andre Raw, said.
Once the agency feels the data from these initiatives are “sufficiently mature,” it intends to communicate the information via a draft guidance, Raw said Oct. 1 at a meeting on...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?